within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX28_Bulevirtide;

model Bulevirtide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 6.75e-08,
    adminDuration = 600,
    adminMass = 2 / 1000000,
    adminCount = 1,
    Vd = 0.00332,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bulevirtide</td></tr><tr><td>ATC code:</td><td>J05AX28</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.32</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.243</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bulevirtide is an entry inhibitor used for the treatment of chronic hepatitis B and D virus infection. It acts by binding to and blocking the sodium taurocholate co-transporting polypeptide (NTCP) receptor on hepatocytes, thereby preventing viral entry. Bulevirtide is approved for medical use in the European Union for chronic hepatitis D infection in adults with compensated liver disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects following subcutaneous administration; population pharmacokinetic modeling.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AX28 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bulevirtide;
